Background
==========

There is an unmet need for the early detection of cardiovascular damage in cancer survivors treated with potentially cardiac toxic medications.[@b1-vhrm-11-591] Current practice relies on the use of left ventricular ejection fraction (LVEF) to document the myocardial impact of doxorubicin. These techniques are insensitive.[@b1-vhrm-11-591]--[@b3-vhrm-11-591] With the development of highly sensitive troponins, more attention has been focused on the predictive value of cardiovascular disease beyond the diagnostic usage for acute coronary syndrome.[@b4-vhrm-11-591]--[@b6-vhrm-11-591] Studies of the general population suggest that those with an elevation in their cardiac troponin are associated with an increase in cardiovascular mortality.[@b7-vhrm-11-591],[@b8-vhrm-11-591] Those individuals with an elevation in their cardiac troponin during the receipt of chemotherapy have also been associated with permanent changes in LVEF.[@b9-vhrm-11-591] Other studies are ongoing using B-natriuretic peptide (BNP) as predictors of cardiac events. We present a small pilot study designed to evaluate whether baseline biomarkers or changes in these biomarkers predict cardiac damage in those patients receiving doxorubicin chemotherapy.

Materials and methods
=====================

We evaluated levels of N-terminal (NT)-proBNP, cardiac troponin T (cTnT), cTnI, and high-sensitivity (hs)-cTnT in 18 consecutive cancer patients \>18 years with a diagnosis of breast cancer (n=14) or non-Hodgkin lymphoma (n=4) receiving anthracycline-based chemotherapy, in order to determine whether baseline levels or changes in these markers (at each follow-up chemotherapy and at 4 weeks following the completion of chemotherapy) may help predict the onset of heart failure. All patients provided written informed consent. The Institutional review board at the University of Minnesota approved this study. All patients were treated at the University of Minnesota Masonic Cancer Center.

All patients underwent equilibrium radionuclide ventriculography (multigated acquisition) in the best septal view after in vivo labeling of red blood cells with technetium-99 m pertechnetate for determination of LVEF prior and 4 weeks after the completion of doxorubicin chemotherapy (E-Cam gamma camera; Siemens AG, Berlin, Germany). While ultrasound cardiography is growing in clinical use, multigated acquisition was the preferred practice at the time of this study. All patients underwent blood draws to evaluate NT-proBNP, cTnT, cTnI, and hscTnT at baseline, before each cycle of chemotherapy and 4 weeks after the completion of chemotherapy. The analytical sensitivity of the cTnI was 0.03 ng/mL. cTnT, hscTnT, and NT-proBNP were measured on an Elecsys 1010 platform (Hoffman-La Roche Ltd, Basel, Switzerland). The analytical sensitivity of the cTnT, hscTnT, and NT-proBNP immunoassays was 0.010 ng/mL, 1 pg/mL, and 3 pg/mL, respectively. Measurements of all biomarkers were performed without knowledge of clinical or LVEF data.

Summary statistics were calculated for all baseline, follow-up, and changes in markers of cTnI, cTnT, hscTnT, NT-proBNP, and LVEF. Patients were followed for up to 4 weeks following the completion of their chemotherapy. Paired *t*-test or Wilcoxon signed-rank test was used for comparing baseline and follow-up markers. *t*-Tests or Wilcoxon rank-sum tests were also used to compare the markers of those with and without declines in LVEF. Spearman correlation was calculated for the change (ie, follow-up minus baseline) in LVEF with baseline and follow-up biomarker values. *P*\<0.05 was considered statistically significant.

Results
=======

A total of 18 patients (16 female, two male) with a median age of 52 years (range 30--72 years) received combination anthracycline-based chemotherapy with a median dose of doxorubicin exposure of 240 (range 240--402) mg/m^2^. All subjects had normal liver and kidney function and no cardiac history. Mean systolic blood pressure was 124.5±14.8 mmHg, while mean diastolic blood pressure was 75.5±9.4 mmHg. Fourteen of 18 patients received therapy for breast cancer; the remainder received chemotherapy for non-Hodgkin lymphoma. No patients received mediastinal radiation. All patients received combination chemotherapy (with cyclophosphamide in those with a diagnosis of breast cancer, and with cyclophosphamide, vincristine, and prednisone in those with a diagnosis of non-Hodgkin lymphoma). No clinical cardiac events were observed during the chemotherapy or within 4 weeks of completing chemotherapy. The median LVEF at baseline was 58% (range 50%--70%). cTnI and cTnT were not detectable at baseline. The median hscTnT at baseline was 1.39 pg/mL. The median NT-proBNP was 46.1 pg/mL (range 28.2--383.4 pg/mL).

Baseline and follow-up variables are outlined in [Table 1](#t1-vhrm-11-591){ref-type="table"}. Following treatment with doxorubicin, hscTnT increased significantly to 19.1 pg/mL (range 0.8--77.2 pg/mL) (*P*,0.001). cTnI and cTnT remained undetectable, while NT-proBNP levels marginally increased to 88.3 pg/mL.

Six of 18 patients had an increase or no change in LVEF (range 0--8.0%). The remaining 12 patients had a median decline in LVEF after treatment of 4.5% (range 2.0%--20.0%). The 12 subjects with a decline in LVEF (n=12, median LVEF after chemotherapy 54%) were compared to those with no change in LVEF (n=6, median LVEF after chemotherapy 64%). Those who experienced a decline in LVEF had higher baseline hscTnT levels in comparison to those who had had no change in LVEF (2.7 pg/mL, 0.1 pg/mL, respectively; *P*=0.07) ([Table 2](#t2-vhrm-11-591){ref-type="table"}). Baseline TnT, TnI, and NT-proBNP were not associated with a decline in LVEF. Spearman correlation demonstrated that patients with a higher baseline hscTnT and creatine kinase MB tended to have a greater decline in LVEF (Spearman correlation −0.54, 95% confidence interval −0.80 to −0.08 \[*P*=0.02\], and −0.49, 95% confidence interval −0.77 to −0.01 \[*P*=0.04\], respectively). Baseline TnT, TnI, and NT-proBNP were not associated with a decline in LVEF. Change in TnT, TnI, and NT-proBNP and hscTnT were not associated with a decline in LVEF. No subjects developed clinical symptoms of heart failure. No subjects had other identifiable causes of cardiomyopathy, myocardial inflammatory disease, or shock.

Discussion
==========

The optimal treatment for chemotherapy-induced cardiomyopathy is prevention. Biomarkers allow individuals at risk for developing long-term cardiac complications to be identified, in many cases before any other clinical evidence is apparent. In our study, we enrolled 18 individuals receiving anthracycline-based chemotherapy. Those individuals with a higher baseline hscTnT were more likely to have a decline in LVEF. While none of these patients developed symptomatic cardiac failure or a decline in their LVEF to below the lower limits of normal, there was a suggestion that those individuals with an elevated baseline hscTnT were more likely to have a significant decline in their LVEF. Declines in LVEF can predispose these subjects to early cardiac failure. While hscTnT can increase for such reasons as dilated cardiomyopathy, myocardial inflammatory disease, and shock, none of our subjects had any other symptoms or history to explain the change in hscTnT other than the receipt of chemotherapy and cardiac injury.

The results of our study are supported by the work of others in both cancer patients and noncancer patients. In noncancer patients, detectable TnI and TnT concentrations have been associated with cardiac failure and were an independent risk factor for cardiac death.[@b8-vhrm-11-591],[@b10-vhrm-11-591],[@b11-vhrm-11-591] Daniels et al found that detectable TnT (with a threshold of 0.01 ng/mL) was associated with increased risk of death (hazard ratio 1.85, *P*\<0.001) in 957 elderly adults (mean age 77 years at baseline).[@b8-vhrm-11-591] Looking at cancer patients, Sawaya et al evaluated the usefulness of hscTnI by looking at values at baseline and 3 and 6 months after chemotherapy with anthracyclines and trastuzumab. hscTnI remained elevated in 28% of patients.[@b12-vhrm-11-591] Detectable hscTnI at 3 months was an independent predictor of developing cardiac dysfunction. While the study by Sawaya et al demonstrated an association between elevations in hscTnT after chemotherapy and a decline in LVEF, our study suggests that individuals with elevated hscTnT at baseline are more likely to have a decline in LVEF.[@b12-vhrm-11-591] Given that elevations in hscTnT have been associated with structural and functional measures of heart disease, it is biologically plausible that individuals with elevated levels of baseline hscTnT levels and levels after treatment may both suggest these subgroups are at higher risk of developing chemotherapy-induced cardiomyopathy.

Our study is limited by its small sample size. Published literature suggests asymptomatic declines in LVEF may occur in up to 30% of individuals receiving chemotherapy for breast cancer and/or lymphoma, and it is possible that our small sample size did not allow for a sample large enough to detect this difference. This study, however, is hypothesis-generating. It suggests that further work should be performed in investigating the utility of baseline cardiac biomarkers in predicting cardiac changes in LVEF. Longer follow-up may allow for better correlation of how these values predict changes in clinical outcome.

Cardiac complications from chemotherapy remain a serious adverse effect of chemotherapy, particularly with anthracycline-based regimens. Early detection with the use of biomarkers remains crucial in evaluating these patients, and in potentially introducing interventions to prevent these long-term complications. Screening individuals who are going to receive anthracyclines with hscTnT may be indicated. Larger, prospective clinical trials are warranted. The results of one such ongoing trial (MANTICORE) are highly anticipated.[@b13-vhrm-11-591],[@b14-vhrm-11-591]
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###### 

Baseline and follow-up cardiac biomarkers of all patients

                     Baseline                At follow-up            Change
  ------------------ ----------------------- ----------------------- -----------------------
  cTnI (ng/mL)       0.00 (0.00, 0.01)       0.05 (0.01, 0.09)       0.04 (0.00, 0.08)
  cTnT (ng/mL)       0.00 (0.00, 0.00)       0.00 (0.00, 0.00)       0.00 (0.00, 0.00)
  CKMB (ng/mL)       0.80 (0.50, 0.80)       1.00 (0.70, 1.50)       0.40 (0.00, 0.90)
  NT-proBNP(pg/mL)   46.10 (34.10, 106.10)   88.30 (67.80, 135.90)   20.50 (−11.50, 88.00)
  hscTnT (pg/mL)     1.39 (0.00, 3.36)       19.10 (5.90, 28.70)     16.90 (4.10, 25.60)
  Pre-MUGA EF (%)    58.00 (56.00, 58.00)    58.00 (53.00, 65.00)    −3.00 (−6.00, 4.00)

**Abbreviations:** cTnI, cardiac troponin I; cTnT, cardiac troponin T; CKMB, creatine kinase MB; NT-proBNP, N-terminal pro-B-type natriuretic peptide; hscTnT, high-sensitivity cTnT; MUGA, multigated acquisition (equilibrium radionuclide ventriculography); EF, ejection fraction.

###### 

Baseline characteristics stratified by change in EF

  Variable            No change in EF decline in EF   *P*-value   
  ------------------- ------------------------------- ----------- ------
  cTnI (ng/mL)        0                               0           0.48
  cTnT (ng/mL)        0                               0           1.00
  CKMB (ng/mL)        0.7                             0.8         0.25
  NT-proBNP (pg/mL)   71.4                            45.5        0.61
  hscTnT (pg/mL)      0.1                             2.7         0.07

**Abbreviations:** cTnI, cardiac troponin I; cTnT, cardiac troponin T; CKMB, creatine kinase MB; NT-proBNP, N-terminal pro-B-type natriuretic peptide; hscTnT, high-sensitivity cTnT; EF, ejection fraction.
